Novo Nordisk Ups Ante in Metsera Bid to $10B, Sparking Legal Battle with Pfizer
Novo Nordisk's revised $10 billion offer for obesity-focused biotech Metsera has triggered a high-stakes corporate showdown with Pfizer. The Danish pharma giant's $86.20/share bid represents a 159% premium to Metsera's undisturbed price, dwarfing Pfizer's $70/share counteroffer. Market reaction was immediate, with NVO shares sliding as investors weighed the bidding war's implications.
Legal artillery now deploys alongside financial firepower. Pfizer alleges antitrust violations in Novo's aggressive move, filing its second lawsuit claiming unfair tactics. 'This isn't just about valuation - it's about preserving competitive balance in metabolic therapeutics,' a Pfizer insider contends. Novo maintains its bid clears regulatory hurdles while accelerating patient access to next-generation obesity treatments.
